Endocrine and targeted therapies have significantly improved the prognostic of hormone positive and human epidermal growth receptor 2 (HER2)-positive breast cancer, respectively, whereas for patients with triple negative BC (TNBC), scarce therapeutic options are available [2]. The gene discussed is ERBB2; the disease is breast carcinoma.